F757 and F605: Unnecessary Drugs and Psychotropic Rules Explained

F757 and F605 are the two federal F-tags that now drive most medication regimen review (MRR) findings in skilled nursing facilities. F757 covers unnecessary drugs of any class. F605, the chemical restraint tag, now also carries the psychotropic medication requirements that used to sit under F758, which CMS retired in its 2025 surveyor guidance update. This post explains what each tag addresses, what changed, and the documentation habits that keep a facility defensible. It is general professional education, not patient-specific clinical, legal, or billing advice.

What changed: F758 is gone, F605 carries psychotropics

In revised State Operations Manual Appendix PP guidance (released in QSO-25-07-NH and, after two delays, used on surveys from April 28, 2025), CMS removed F758, "Free from Unnecessary Psychotropic Meds/PRN Use." Its regulation text, interpretive guidance, and surveyor procedures were moved into F605, "Right to be Free from Chemical Restraints."

The practical effect is a change of framing. Psychotropic use that is not clinically indicated, not individualized, or used for staff convenience or discipline is now evaluated through the chemical-restraint lens. Facility policies, MRR templates, survey-readiness checklists, and training material that still cite F758 should be updated to F605.

CMS continues to revise its guidance, so confirm the current language directly at cms.gov rather than relying on memory or secondhand summaries.

F757: the "unnecessary drug" framework

F757 applies to every medication class. It is not a list of forbidden drugs; it is a framework surveyors use to ask whether each medication a resident receives is still justified. The classic dimensions a consultant pharmacist evaluates include whether a medication is used:

• Without an adequate clinical indication for its use.
• In an excessive dose, including duplicate therapy within the same drug class.
• For an excessive duration beyond what the indication supports.
• Without adequate monitoring for effectiveness and adverse effects.
• In the presence of adverse consequences that indicate the drug should be reduced or discontinued.

A medication is not "unnecessary" simply because it appears on a screening list. It becomes a finding when the record cannot support its continued use. That distinction is where good documentation protects a facility.

F605: psychotropic medications and gradual dose reduction

Under F605, psychotropic medications, including antipsychotics, antidepressants, antianxiety agents, and sedative-hypnotics, must be clinically indicated, individualized, and periodically reconsidered. The regulatory intent is to keep psychotropics from substituting for individualized, person-centered care. A psychotropic given without an adequate indication, or primarily to manage behavior for staff convenience, can be cited as a chemical restraint.

Two concepts anchor F605 psychotropic compliance in practice: adequate indication and gradual dose reduction (GDR). GDR is the stepwise, documented effort to taper a psychotropic to the lowest effective dose, or to discontinue it, unless clinically contraindicated. The record should show that GDR was attempted on the expected schedule, or that a clinically justified reason to defer it was documented.

Informed consent and PRN orders

The 2025 guidance also places more emphasis on resident or representative involvement in psychotropic decisions, including discussion of risks, benefits, and alternatives. Surveyor concern continues to center on whether the diagnosis supports use, whether nonpharmacologic approaches were tried and documented, and whether as-needed (PRN) psychotropic orders are reassessed rather than renewed indefinitely.

Do not rely on generic figures for PRN time limits or GDR intervals from blog posts or vendor decks. These are defined in current CMS guidance; verify the specifics against the official guidance before building them into facility policy.

Where clinical criteria fit

Published clinical criteria give your MRR a defensible, evidence-informed spine. The American Geriatrics Society (AGS) Beers Criteria flag medications that are potentially inappropriate in older adults. STOPP criteria describe potentially inappropriate prescribing. Anticholinergic burden (ACB) scales help quantify cumulative anticholinergic exposure, which is relevant to both fall risk and cognition.

These criteria inform, but do not replace, the pharmacist's judgment. A Beers-flagged medication may be entirely appropriate for a given resident; the point is that the flag prompts a documented evaluation. Criteria are periodically revised, so cite the version you used and keep current.

Building a defensible record

Most F757 and F605 psychotropic citations are not failures of clinical care; they are failures of documentation. The care may be sound, but the record does not show the reasoning. Build these habits into every MRR:

1. Tie every flagged drug to an indication. State the clinical reason the medication is continued, or recommend a change if the indication is absent or outdated.
2. Document monitoring. Note what is being followed to confirm effectiveness and to detect adverse consequences.
3. Address GDR explicitly. For psychotropics, record whether GDR was attempted, its outcome, or the specific clinical justification for deferring it.
4. Capture nonpharmacologic efforts and consent. For behavioral symptoms, show that non-drug approaches were considered or tried, and that the resident or representative was involved in the decision.
5. Close the loop. Track each recommendation to acceptance, rejection with rationale, or action by the prescriber. An open recommendation with no response is a survey vulnerability.
6. Update your references. Replace F758 citations in policies, templates, and checklists with F605.

Survey readiness between surveys

Survey readiness is a continuous state, not a pre-survey scramble. Facilities that do well treat each monthly MRR as the evidence they would hand a surveyor on any given day: consistent formatting, time-stamped sign-off, and an audit trail showing who reviewed what, when, and what happened next. For how we think about data integrity and verifiable records, see our trust center, and for a checklist approach see survey readiness.

Common pitfalls to avoid

• Still citing F758 in policies or recommendations after the 2025 guidance change.
• Treating a screening flag as an automatic recommendation instead of a prompt to evaluate.
• Recommending a GDR without documenting the clinical rationale either way.
• Letting PRN psychotropic orders renew without a reassessment note.
• Leaving prescriber responses uncaptured, so the record cannot show the loop was closed.

How WeConsultRx helps

WeConsultRx turns F757 and F605 readiness into a repeatable workflow. Codified clinical rule packs surface potentially inappropriate medications for the consultant pharmacist to evaluate, findings map to the relevant CMS F-tags, GDR attempts are tracked per resident, and recommendations follow through prescriber response and consultant e-signature sign-off into an append-only audit log. The outcome is a cleaner, faster MRR and a record you can stand behind at survey. Request a demo to see the compliance workflow in action.

Frequently asked questions